Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs PubMatic Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while PubMatic Inc trades at $18.64 (market cap $850.88M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 7.1× PubMatic Inc's market cap, and PubMatic Inc is more actively traded (997,698 versus 14,805,993). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and PubMatic Inc for 40 Days on average.
| IOVA | PUBM | |
|---|---|---|
Market Cap | $6.04B | $850.88M |
Volume | 14,805,993 | 997,698 |
Sector | Health | Technology |
52-Week High | $14.82 | $19.18 |
52-Week Low | $1.81 | $6.28 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $5.97B | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PubMatic (PUBM) trades at $18.68, up 0.59% with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with revenue growth of 11% year-over-year and an EPS beat, though profitability remains challenged with negative net margins. Recent leadership appointments and AI product developments signal strategic focus on growth. Analyst consensus is bullish with 11 buy ratings and a $19.89 price target, representing 6.5% upside potential.
The stock presents a growth opportunity in digital advertising technology with AI-driven products gaining traction, but faces execution risks amid negative profitability and competitive pressures. Revenue growth acceleration and margin improvement will be critical for sustained upside, while current valuation multiples remain elevated relative to earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
